{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,30]],"date-time":"2026-10-30T05:00:01Z","timestamp":1793336401148,"version":"4.5.0"},"reference-count":51,"publisher":"Elsevier BV","issue":"11","license":[{"start":{"date-parts":[[2024,11,1]],"date-time":"2024-11-01T00:00:00Z","timestamp":1730419200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,11,1]],"date-time":"2024-11-01T00:00:00Z","timestamp":1730419200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,7,24]],"date-time":"2024-07-24T00:00:00Z","timestamp":1721779200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100003399","name":"Shanghai Municipality Science and Technology Commission","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100003399","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Acta Pharmaceutica Sinica B"],"published-print":{"date-parts":[[2024,11]]},"DOI":"10.1016\/j.apsb.2024.07.019","type":"journal-article","created":{"date-parts":[[2024,8,2]],"date-time":"2024-08-02T22:54:42Z","timestamp":1722639282000},"page":"4914-4933","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":11,"title":["Discovery of novel small molecules targeting hepatitis B virus core protein from marine natural products with HiBiT-based high-throughput screening"],"prefix":"10.1016","volume":"14","author":[{"given":"Chao","family":"Huang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yang","family":"Jin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Panpan","family":"Fu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kongying","family":"Hu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mengxue","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wenjing","family":"Zai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ting","family":"Hua","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xinluo","family":"Song","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jianyu","family":"Ye","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yiqing","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gan","family":"Luo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Haiyu","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiangxia","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jieliang","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xuwen","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhenghong","family":"Yuan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.apsb.2024.07.019_bib1","doi-asserted-by":"crossref","first-page":"827","DOI":"10.1038\/s41573-019-0037-0","article-title":"Therapeutic strategies for hepatitis B virus infection: towards a cure","volume":"18","author":"Fanning","year":"2019","journal-title":"Nat Rev Drug Discov"},{"key":"10.1016\/j.apsb.2024.07.019_bib2","doi-asserted-by":"crossref","first-page":"1972","DOI":"10.1136\/gutjnl-2015-309809","article-title":"HBV cccDNA: viral persistence reservoir and key obstacle for a cure of chronic hepatitis B","volume":"64","author":"Nassal","year":"2015","journal-title":"Gut"},{"key":"10.1016\/j.apsb.2024.07.019_bib3","doi-asserted-by":"crossref","DOI":"10.1016\/j.antiviral.2020.104925","article-title":"Hepatitis B virus biology and life cycle","volume":"182","author":"Tsukuda","year":"2020","journal-title":"Antivir Res"},{"key":"10.1016\/j.apsb.2024.07.019_bib4","unstructured":"World Health Organization. Hepatitis B. Available from: https:\/\/www.who.int\/zh\/news-room\/fact-sheets\/detail\/hepatitis-b."},{"key":"10.1016\/j.apsb.2024.07.019_bib5","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1016\/j.jhep.2016.02.021","article-title":"Mechanisms of HBV-induced hepatocellular carcinoma","volume":"64","author":"Levrero","year":"2016","journal-title":"J Hepatol"},{"key":"10.1016\/j.apsb.2024.07.019_bib6","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1038\/nrgastro.2016.7","article-title":"Global strategies are required to cure and eliminate HBV infection","volume":"13","author":"Revill","year":"2016","journal-title":"Nat Rev Gastroenterol Hepatol"},{"key":"10.1016\/j.apsb.2024.07.019_bib7","article-title":"HBV replication inhibitors","volume":"179","author":"Pierra","year":"2020","journal-title":"Antivir Res"},{"key":"10.1016\/j.apsb.2024.07.019_bib8","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1021\/acsinfecdis.7b00144","article-title":"Discovery of small molecule therapeutics for treatment of chronic HBV infection","volume":"4","author":"Feng","year":"2018","journal-title":"ACS Infect Dis"},{"key":"10.1016\/j.apsb.2024.07.019_bib9","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1016\/j.antiviral.2011.08.012","article-title":"The main hepatitis B virus (HBV) mutants resistant to nucleoside analogs are susceptible in\u00a0vitro to non-nucleoside inhibitors of HBV replication","volume":"92","author":"Billioud","year":"2011","journal-title":"Antivir Res"},{"key":"10.1016\/j.apsb.2024.07.019_bib10","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1016\/j.coviro.2018.04.006","article-title":"Perspectives and limitations for nucleo(t)side analogs in future HBV therapies","volume":"30","author":"Levrero","year":"2018","journal-title":"Curr Opin Virol"},{"key":"10.1016\/j.apsb.2024.07.019_bib11","doi-asserted-by":"crossref","first-page":"1296","DOI":"10.1002\/hep.29323","article-title":"Hepatitis B cure: from discovery to regulatory approval","volume":"66","author":"Lok","year":"2017","journal-title":"Hepatology"},{"key":"10.1016\/j.apsb.2024.07.019_bib12","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2021.733364","article-title":"Interferon and hepatitis B: current and future perspectives","volume":"12","author":"Ye","year":"2021","journal-title":"Front Immunol"},{"key":"10.1016\/j.apsb.2024.07.019_bib13","doi-asserted-by":"crossref","DOI":"10.1128\/AAC.00465-18","article-title":"Identification of retinoic acid receptor agonists as potent hepatitis B virus inhibitors via a drug repurposing screen","volume":"62","author":"Li","year":"2018","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.apsb.2024.07.019_bib14","doi-asserted-by":"crossref","first-page":"1275","DOI":"10.1002\/hep.32245","article-title":"HBV covalently closed circular DNA minichromosomes in distinct epigenetic transcriptional states differ in their vulnerability to damage","volume":"75","author":"Wang","year":"2022","journal-title":"Hepatology"},{"key":"10.1016\/j.apsb.2024.07.019_bib15","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1016\/j.antiviral.2015.06.020","article-title":"Core protein: a pleiotropic keystone in the HBV lifecycle","volume":"121","author":"Zlotnick","year":"2015","journal-title":"Antivir Res"},{"key":"10.1016\/j.apsb.2024.07.019_bib16","doi-asserted-by":"crossref","first-page":"771","DOI":"10.1016\/S1097-2765(01)80009-5","article-title":"The crystal structure of the human hepatitis B virus capsid","volume":"3","author":"Wynne","year":"1999","journal-title":"Mol Cel"},{"key":"10.1016\/j.apsb.2024.07.019_bib17","doi-asserted-by":"crossref","first-page":"15196","DOI":"10.1073\/pnas.1513803112","article-title":"High-resolution crystal structure of a hepatitis B virus replication inhibitor bound to the viral core protein","volume":"112","author":"Klumpp","year":"2015","journal-title":"Proc Natl Acad Sci"},{"key":"10.1016\/j.apsb.2024.07.019_bib18","doi-asserted-by":"crossref","DOI":"10.1016\/j.antiviral.2020.104917","article-title":"Targeting the multifunctional HBV core protein as a potential cure for chronic hepatitis B","volume":"182","author":"Viswanathan","year":"2020","journal-title":"Antivir Res"},{"key":"10.1016\/j.apsb.2024.07.019_bib19","doi-asserted-by":"crossref","DOI":"10.1038\/srep38959","article-title":"HBV maintains electrostatic homeostasis by modulating negative charges from phosphoserine and encapsidated nucleic acids","volume":"6","author":"Su","year":"2016","journal-title":"Sci Rep"},{"key":"10.1016\/j.apsb.2024.07.019_bib20","doi-asserted-by":"crossref","first-page":"5830","DOI":"10.1128\/JVI.00394-16","article-title":"Cell-free hepatitis B virus capsid assembly dependent on the core protein C-terminal domain and regulated by phosphorylation","volume":"90","author":"Ludgate","year":"2016","journal-title":"J Virol"},{"key":"10.1016\/j.apsb.2024.07.019_bib21","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1016\/j.antiviral.2017.11.015","article-title":"The diverse functions of the hepatitis B core\/capsid protein (HBc) in the viral life cycle: implications for the development of HBc-targeting antivirals","volume":"149","author":"Diab","year":"2018","journal-title":"Antivir Res"},{"key":"10.1016\/j.apsb.2024.07.019_bib22","doi-asserted-by":"crossref","first-page":"1708","DOI":"10.1021\/acschembio.0c00320","article-title":"Local stabilization of subunit\u2013subunit contacts causes global destabilization of hepatitis B virus capsids","volume":"15","author":"Schlicksup","year":"2020","journal-title":"ACS Chem Biol"},{"key":"10.1016\/j.apsb.2024.07.019_bib23","doi-asserted-by":"crossref","DOI":"10.1016\/j.bmcl.2022.128823","article-title":"Diazepinone HBV capsid assembly modulators","volume":"72","author":"Kuduk","year":"2022","journal-title":"Bioorg Med Chem Lett"},{"key":"10.1016\/j.apsb.2024.07.019_bib24","doi-asserted-by":"crossref","first-page":"7651","DOI":"10.1021\/acs.jmedchem.6b00879","article-title":"Design and synthesis of orally bioavailable 4-methyl heteroaryldihydropyrimidine based hepatitis B virus (HBV) capsid inhibitors","volume":"59","author":"Qiu","year":"2016","journal-title":"J Med Chem"},{"key":"10.1016\/j.apsb.2024.07.019_bib25","doi-asserted-by":"crossref","first-page":"2782","DOI":"10.1073\/pnas.1308846110","article-title":"Thermodynamic origins of protein folding, allostery, and capsid formation in the human hepatitis B virus core protein","volume":"110","author":"Alexander","year":"2013","journal-title":"Proc Natl Acad Sci"},{"key":"10.1016\/j.apsb.2024.07.019_bib26","doi-asserted-by":"crossref","first-page":"2184","DOI":"10.1038\/s41467-019-10200-5","article-title":"Ciclopirox inhibits hepatitis B virus secretion by blocking capsid assembly","volume":"10","author":"Kang","year":"2019","journal-title":"Nat Commun"},{"key":"10.1016\/j.apsb.2024.07.019_bib27","doi-asserted-by":"crossref","first-page":"542","DOI":"10.1002\/jmr.801","article-title":"BAY 41-4109 has multiple effects on hepatitis B virus capsid assembly","volume":"19","author":"Stray","year":"2010","journal-title":"J Mol Recognit"},{"key":"10.1016\/j.apsb.2024.07.019_bib28","doi-asserted-by":"crossref","first-page":"793","DOI":"10.3851\/IMP2152","article-title":"In\u00a0vitro inhibition of HBV replication by a novel compound, GLS4, and its efficacy against adefovir-dipivoxil-resistant HBV mutations","volume":"17","author":"Wang","year":"2012","journal-title":"Antivir Ther"},{"key":"10.1016\/j.apsb.2024.07.019_bib29","doi-asserted-by":"crossref","first-page":"3352","DOI":"10.1021\/acs.jmedchem.7b00083","article-title":"Discovery and pre-clinical characterization of third-generation 4-H heteroaryldihydropyrimidine (HAP) analogues as hepatitis B virus (HBV) capsid inhibitors","volume":"60","author":"Qiu","year":"2017","journal-title":"J Med Chem"},{"key":"10.1016\/j.apsb.2024.07.019_bib30","doi-asserted-by":"crossref","first-page":"1355","DOI":"10.1021\/acs.jmedchem.7b01914","article-title":"3-((R)-4-(((R)-6-(2-Bromo-4-fluorophenyl)-5-(ethoxycarbonyl)-2-(thiazol-2-yl)-3,6-dihydropyrimidin-4-yl)methyl)morpholin-2-yl)propanoic acid (HEC72702), a novel hepatitis B virus capsid inhibitor based on clinical candidate GLS4","volume":"61","author":"Ren","year":"2018","journal-title":"J Med Chem"},{"key":"10.1016\/j.apsb.2024.07.019_bib31","doi-asserted-by":"crossref","first-page":"4253","DOI":"10.1021\/acs.jmedchem.3c00173","article-title":"Discovery of linvencorvir (RG7907), a hepatitis B virus core protein allosteric modulator, for the treatment of chronic HBV infection","volume":"66","author":"Zhang","year":"2023","journal-title":"J Med Chem"},{"key":"10.1016\/j.apsb.2024.07.019_bib32","doi-asserted-by":"crossref","DOI":"10.1128\/AAC.00082-18","article-title":"Preclinical profile of AB-423, an inhibitor of hepatitis B virus pregenomic RNA encapsidation","volume":"62","author":"Mani","year":"2018","journal-title":"Antimicrob Agents Ch"},{"key":"10.1016\/j.apsb.2024.07.019_bib33","doi-asserted-by":"crossref","first-page":"2687","DOI":"10.1016\/S0960-894X(00)00544-8","article-title":"Phenylpropenamide derivatives as inhibitors of hepatitis B virus replication","volume":"10","author":"Perni","year":"2000","journal-title":"Bioorg Med Chem Lett"},{"key":"10.1016\/j.apsb.2024.07.019_bib34","doi-asserted-by":"crossref","first-page":"6247","DOI":"10.1021\/acs.jmedchem.8b00654","article-title":"Synthesis and evaluation of N-phenyl-3-sulfamoyl-benzamide derivatives as capsid assembly modulators inhibiting hepatitis B virus (HBV)","volume":"61","author":"Vandyck","year":"2018","journal-title":"J Med Chem"},{"key":"10.1016\/j.apsb.2024.07.019_bib35","doi-asserted-by":"crossref","first-page":"13968","DOI":"10.1021\/acs.jmedchem.3c01022","article-title":"Design, synthesis, and biological evaluation of novel thioureidobenzamide (TBA) derivatives as HBV capsid assembly modulators","volume":"66","author":"Wang","year":"2023","journal-title":"J Med Chem"},{"key":"10.1016\/j.apsb.2024.07.019_bib36","doi-asserted-by":"crossref","DOI":"10.1128\/AAC.01463-20","article-title":"Preclinical profile and characterization of the hepatitis B virus core protein inhibitor ABI-H0731","volume":"64","author":"Huang","year":"2020","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.apsb.2024.07.019_bib37","doi-asserted-by":"crossref","first-page":"3457","DOI":"10.1002\/hep4.2095","article-title":"Safety, pharmacokinetics, and antiviral activity of the capsid inhibitor AB-506 from Phase 1 studies in healthy subjects and those with hepatitis B","volume":"6","author":"Yuen","year":"2022","journal-title":"Hepatol Commun"},{"key":"10.1016\/j.apsb.2024.07.019_bib38","doi-asserted-by":"crossref","first-page":"528","DOI":"10.3390\/md20080528","article-title":"Marine natural products in clinical use","volume":"20","author":"Haque","year":"2022","journal-title":"Mar Drugs"},{"key":"10.1016\/j.apsb.2024.07.019_bib39","doi-asserted-by":"crossref","first-page":"770","DOI":"10.1021\/acs.jnatprod.9b01285","article-title":"Natural products as sources of new drugs over the nearly four decades from 01\/1981 to 09\/2019","volume":"83","author":"Newman","year":"2020","journal-title":"J Nat Prod"},{"key":"10.1016\/j.apsb.2024.07.019_bib40","doi-asserted-by":"crossref","first-page":"112790","DOI":"10.1016\/j.ejmech.2020.112790","article-title":"Antiviral potential of natural products from marine microbes","volume":"207","author":"Yi","year":"2020","journal-title":"Eur J Med Chem"},{"key":"10.1016\/j.apsb.2024.07.019_bib41","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1016\/j.antiviral.2010.03.009","article-title":"Marine compounds and their antiviral activities","volume":"86","author":"Yasuhara-Bell","year":"2010","journal-title":"Antivir Res"},{"key":"10.1016\/j.apsb.2024.07.019_bib42","doi-asserted-by":"crossref","first-page":"11298","DOI":"10.1021\/acs.jmedchem.8b01430","article-title":"Design and synthesis of marine phidianidine derivatives as potential immunosuppressive agents","volume":"61","author":"Liu","year":"2018","journal-title":"J Med Chem"},{"key":"10.1016\/j.apsb.2024.07.019_bib43","doi-asserted-by":"crossref","first-page":"5427","DOI":"10.1021\/acs.jmedchem.2c01702","article-title":"Bioactivity-driven synthesis of the marine natural product naamidine J and its derivatives as potential tumor immunological agents by inhibiting programmed death-ligand 1","volume":"66","author":"Fu","year":"2023","journal-title":"J Med Chem"},{"key":"10.1016\/j.apsb.2024.07.019_bib44","doi-asserted-by":"crossref","first-page":"467","DOI":"10.1021\/acschembio.7b00549","article-title":"CRISPR-mediated tagging of endogenous proteins with a luminescent peptide","volume":"13","author":"Schwinn","year":"2018","journal-title":"ACS Chem Biol"},{"key":"10.1016\/j.apsb.2024.07.019_bib45","doi-asserted-by":"crossref","first-page":"6958","DOI":"10.1021\/acs.joc.7b00639","article-title":"Regioselective base-mediated cyclizations of mono-N-acylpropargylguanidines","volume":"82","author":"Salvant","year":"2017","journal-title":"J Org Chem"},{"key":"10.1016\/j.apsb.2024.07.019_bib46","first-page":"205","article-title":"Antiviral profiling of the capsid assembly modulator BAY41-4109 on full-length HBV genotype A-H clinical isolates and core site-directed mutants in\u00a0vitro. Antiviral Res","volume":"144","author":"Berke","year":"2017"},{"key":"10.1016\/j.apsb.2024.07.019_bib47","doi-asserted-by":"crossref","first-page":"354","DOI":"10.1080\/22221751.2019.1584018","article-title":"Hepatitis B virus mutation pattern rtL180M+A181C+M204V may contribute to entecavir resistance in clinical practice","volume":"8","author":"Liu","year":"2019","journal-title":"Emerging Microbes Infect"},{"key":"10.1016\/j.apsb.2024.07.019_bib48","article-title":"Amino acid residues at core protein dimer\u2012dimer interface modulate multiple steps of hepatitis B virus replication and HBeAg biogenesis","volume":"17","author":"Hu","year":"2021","journal-title":"PLoS Pathog"},{"key":"10.1016\/j.apsb.2024.07.019_bib49","doi-asserted-by":"crossref","DOI":"10.1016\/j.antiviral.2021.105080","article-title":"Identification of hepatitis B virus core protein residues critical for capsid assembly, pgRNA encapsidation and resistance to capsid assembly modulators","volume":"191","author":"Luo","year":"2021","journal-title":"Antivir Res"},{"key":"10.1016\/j.apsb.2024.07.019_bib50","doi-asserted-by":"crossref","first-page":"893","DOI":"10.1126\/science.1077215","article-title":"Inhibition of hepatitis B virus replication by drug-induced depletion of nucleocapsids","volume":"299","author":"Deres","year":"2003","journal-title":"Science"},{"key":"10.1016\/j.apsb.2024.07.019_bib51","doi-asserted-by":"crossref","DOI":"10.1371\/journal.ppat.1010204","article-title":"Bay41-4109-induced aberrant polymers of hepatitis b capsid proteins are removed via STUB1-promoted p62-mediated macroautophagy","volume":"18","author":"Lin","year":"2022","journal-title":"PLoS Pathog"}],"container-title":["Acta Pharmaceutica Sinica B"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2211383524003095?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2211383524003095?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,11,22]],"date-time":"2024-11-22T15:14:32Z","timestamp":1732288472000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2211383524003095"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,11]]},"references-count":51,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2024,11]]}},"alternative-id":["S2211383524003095"],"URL":"https:\/\/doi.org\/10.1016\/j.apsb.2024.07.019","relation":{},"ISSN":["2211-3835"],"issn-type":[{"value":"2211-3835","type":"print"}],"subject":[],"published":{"date-parts":[[2024,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Discovery of novel small molecules targeting hepatitis B virus core protein from marine natural products with HiBiT-based high-throughput screening","name":"articletitle","label":"Article Title"},{"value":"Acta Pharmaceutica Sinica B","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.apsb.2024.07.019","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 The Authors. Published by Elsevier B.V. on behalf of Chinese Pharmaceutical Association and Institute of Materia Medica, Chinese Academy of Medical Sciences.","name":"copyright","label":"Copyright"}]}}